| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.16 | 0.6 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.6 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |